Prostate Cancer Metastatic
Conditions
Brief summary
This is a phase II randomised, double-blind, dose finding, repeat dose Phase II multicentre study of ODX for the treatment of patients with castration resistant prostate cancer (CRPC) and skeletal metastases. The primary objective is to evaluate the relative change from baseline in response markers related to bone metabolism (alkaline phosphatase (B-ALP) and S P1NP) at 12 weeks of three different doses of ODX (3.0, 6.0 and 9.0 mg/kg ODX).
Detailed description
Males, diagnosed with CRPC, who fulfil the inclusion criteria and does not have any exclusion criteria, will be asked to participate in the study. The subject will be informed orally and in writing about the study procedures and give written informed consent, prior to study start. At the screening visit the following examinations are performed: Physical examination, medical history and concomitant medication. Heart rate, blood pressure, weight, height, body temperature and respiratory rate are measured. Blood samples are drawn and urine sample is collected. ECG is recorded. Bone scan and diagnostic CT scan are also performed. At the next visit, baseline, the subject is examined physically and heart rate, blood pressure, weight, body temperature and respiratory rate are measured, ECG is recorded, blood samples drawn and urine sample collected. FACT-P and EQ-5D-5L (European Quality of Life - 5 Dimensions with 5 levels) questionnaire are filled out by the subject. Adverse events and concomitant medication is documented and the first dose of the investigational product is given. The subject is surveyed for 3 hours at the hospital. The duration of the study for the individual subject will be approximately 20 weeks from screening to the follow-up visit 2 weeks after the last dose. Each subject will receive 10 doses of investigational product. After the follow-up visit, the subject enters to long-term follow-up phase which lasts approximately 2 years. A Data Monitoring Committee (DMC) will be designated and will be responsible to monitor/review all study related safety data. After review of safety data the DMC will provide recommendation as to whether the dose escalation can proceed as planned according to the protocol.
Interventions
DRUGOsteodex
formulation: solution for infusion route of administration: intravenous infusion
Sponsors
DexTech Medical AB
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)
Eligibility
Sex/Gender
MALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Age ≥18 years at the time of signing the informed consent form 2. Histologically or cytologically confirmed diagnosis of adenocarcinoma of the prostate 3. Evidence of disease progression based on changes in metastatic bone disease (≥2 bone lesions compared to a prior examination) in bone scan and/or other imaging modality AND/OR evidence of PSA progression in the three consecutive determinations at minimum of 1 week intervals 4. Castrate level of serum testosterone ≤1.7 nmol/L 5. Performance status ECOG 0-2 6. Laboratory requirements: Haematology: Neutrophils ≥ 1.5 x 109/l Haemoglobin ≥ 90 g/l Platelets ≥ 100 x 109/l Hepatic function: Total S-bilirubin ≤ 1.5 times the upper limit of normal (ULN) AST (SGOT) / ALT (SGPT) ≤ 2.5 times ULN or ≤ 5 times ULN in patients with known liver metastases Renal function: S-creatinine (S-Cr)≤ 1.5 times ULN 7. No evidence (≤ 5 years) of prior malignancies (except successfully treated basal cell or squamous cell carcinoma of the skin) 8. Able to adhere to the study visit schedule and other protocol requirements Life expectancy ≥6 months
Exclusion criteria
1. Concurrent use of other anti-cancer agents or treatments, with the following exception: a stable dose of Luteinizing Hormone-Releasing Hormone (LHRH) agonist/antagonist or polyestradiol phosphate. Washout period: bicalutamide 6 weeks; flutamide 4 weeks; abiraterone / enzalutamide 6 weeks, chemotherapy 4 weeks; Radium-223 4 weeks; Strontium-89 or Samarium-153 6 months. 2. Any treatment modalities involving palliative radiation therapy or major surgery within 4 weeks prior to treatment in this study 3. Simultaneous participation in any other study involving investigational drugs or having participated in a study less than 4 weeks prior to start of study treatment 4. Any condition, including the presence of laboratory abnormalities, which confounds the ability to interpret data from the study or places the patient at unacceptable risk if he participates in the study 5. Known brain metastases 6. Dental surgery (dental extraction), periodontal disease, local trauma including poorly fitting dentures within 6 months prior to the first dose of study drug 7. Treatment with bisphosphonates or denosumab within 4 weeks prior to first dose of study medication
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Relative change from baseline in response markers related to bone metabolism (B-ALP and S P1NP). | Baseline and 20 weeks of treatment |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, defined as the time from randomisation to the date of death from any cause. | Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks |
| Change from baseline in response markers related to bone metabolism (B-ALP and S P1NP) at each time point sampled (except 12 weeks). | Baseline and 20 weeks of treatment |
| Change from baseline in response markers related to bone metabolism (Serum C-Terminal Telopeptide (S-CTX) and osteocalcin) at each time point sampled. | Baseline and 20 weeks of treatment |
| Change from baseline in Prostate Specific Antigen (PSA) at each time point sampled. | Baseline and 20 weeks of treatment |
| Time to PSA progression | Baseline and 20 weeks of treatment |
| Time to ALP progression | Baseline and 20 weeks of treatment |
| Time to P1NP progression | Baseline and 20 weeks of treatment |
| Time to progression in bone | Baseline and 20 weeks of treatment |
| Time to progression in soft tissue | Baseline and 20 weeks of treatment |
| Progression free survival, defined as the time from study entry to the date of disease progression or death from any cause. | Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks |
| Therapy response based on changes from baseline according to Response Evaluation Criteria In Solid Tumors (RECIST) based on diagnostic CT in patients with measurable soft tissue metastases. | Baseline and 20 weeks of treatment |
| Changes from baseline in bone metastasis by means of bone scan at each time point examined. | Baseline and 20 weeks of treatment |
| Occurrence of symptomatic skeletal events | Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks |
| Pain (FACT-P questionnaire) | Baseline and 20 weeks of treatment |
| Pain (EQ-5D-5L questionnaire) | Baseline and 20 weeks of treatment |
| Quality of life (EQ-5D-5L questionnaire) | Baseline and 20 weeks of treatment |
| Incidence, causality and intensity of Adverse Events (AEs) | Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks |
| Dose and duration of medications required for the treatment of AEs | Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks |
| Use of analgesics as reported by the patient during treatment and follow-up | Baseline, 20 weeks of treatment and long-term follow-up up to 24 weeks |
Countries
Estonia, Finland, Latvia, Sweden
Outcome results
None listed